Watanabe Tokiko, Kawakami Eiryo, Shoemaker Jason E, Lopes Tiago J S, Matsuoka Yukiko, Tomita Yuriko, Kozuka-Hata Hiroko, Gorai Takeo, Kuwahara Tomoko, Takeda Eiji, Nagata Atsushi, Takano Ryo, Kiso Maki, Yamashita Makoto, Sakai-Tagawa Yuko, Katsura Hiroaki, Nonaka Naoki, Fujii Hiroko, Fujii Ken, Sugita Yukihiko, Noda Takeshi, Goto Hideo, Fukuyama Satoshi, Watanabe Shinji, Neumann Gabriele, Oyama Masaaki, Kitano Hiroaki, Kawaoka Yoshihiro
ERATO Infection-Induced Host Responses Project, Japan Science and Technology Agency, Saitama 332-0012, Japan; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan.
ERATO Infection-Induced Host Responses Project, Japan Science and Technology Agency, Saitama 332-0012, Japan.
Cell Host Microbe. 2014 Dec 10;16(6):795-805. doi: 10.1016/j.chom.2014.11.002. Epub 2014 Nov 20.
Host factors required for viral replication are ideal drug targets because they are less likely than viral proteins to mutate under drug-mediated selective pressure. Although genome-wide screens have identified host proteins involved in influenza virus replication, limited mechanistic understanding of how these factors affect influenza has hindered potential drug development. We conducted a systematic analysis to identify and validate host factors that associate with influenza virus proteins and affect viral replication. After identifying over 1,000 host factors that coimmunoprecipitate with specific viral proteins, we generated a network of virus-host protein interactions based on the stage of the viral life cycle affected upon host factor downregulation. Using compounds that inhibit these host factors, we validated several proteins, notably Golgi-specific brefeldin A-resistant guanine nucleotide exchange factor 1 (GBF1) and JAK1, as potential antiviral drug targets. Thus, virus-host interactome screens are powerful strategies to identify targetable host factors and guide antiviral drug development.
病毒复制所需的宿主因子是理想的药物靶点,因为与病毒蛋白相比,它们在药物介导的选择压力下发生突变的可能性较小。尽管全基因组筛选已鉴定出参与流感病毒复制的宿主蛋白,但对这些因子如何影响流感的机制了解有限,这阻碍了潜在的药物开发。我们进行了一项系统分析,以鉴定和验证与流感病毒蛋白相关并影响病毒复制的宿主因子。在鉴定出1000多个与特定病毒蛋白共免疫沉淀的宿主因子后,我们基于宿主因子下调后受影响的病毒生命周期阶段,生成了一个病毒-宿主蛋白相互作用网络。使用抑制这些宿主因子的化合物,我们验证了几种蛋白质,特别是高尔基体特异性布雷菲德菌素A抗性鸟嘌呤核苷酸交换因子1(GBF1)和JAK1,作为潜在的抗病毒药物靶点。因此,病毒-宿主相互作用组筛选是识别可靶向宿主因子并指导抗病毒药物开发的有力策略。